Rick Gonzalez, AbbVie’s founding CEO, is working on his exit after more than a decade at the helm — and it’s going to be an internal candidate.
Gonzalez first announced the hunt for his successor last year, which included his plans to stay until the company navigated the loss of Humira exclusivity and “the rest of the business is performing at a high level.”
Revenue from its immunology portfolio came in about 10% lower, at $26 billion in 2023, due to biosimilar competition for Humira, but it’s not all bad news. AbbVie raised its long-term outlook for Skyrizi and Rinvoq, saying it now expects combined revenues of more than $27 billion in 2027. That’s about $6 billion higher than previous guidance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.